Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Engineering of Allogeneic Regulatory T Cells Expressing a Chimeric Antigen Receptor(Allo-CAR-Tregs) Using Zinc Finger Nuclease/AAV6-Mediated Editing

Download PDF